Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367835
Status:
COMPLETED
Last Update Posted:
2021-06-14
First Post:
2006-08-22
Brief Title:
SPD503 Guanfacine Hydrochloride in ADHD Plus Oppositional Symptoms
Sponsor:
Shire
Organization:
Takeda
Study Overview
Official Title:
A Double-Blind Randomized Multi-Center Flexible Dose Study Evaluating the Efficacy and Safety of SPD503 Guanfacine Hydrochloride in Children Aged 6-12 With Symptoms of Oppositionality and a Diagnosis of Attention DeficitHyperactivity Disorder
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess efficacy and safety of SPD503guanfacine hydrochloride in subjects with ADHD and oppositional symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None